Tango Therapeutics, Inc. (TNGX)

CIK 0001819133 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q1-2026 8-K (2026-05-13) · 99.1
Latest FY-2025 8-K (2026-03-05) · 99.1  |  8-K (2026-01-08) · 99.1 · 99.2
Q3-2025 8-K (2025-11-04) · 99.1  |  8-K (2025-10-23) · 99.1
Q2-2025 8-K (2025-08-05) · 99.1
Q1-2025 8-K (2025-05-12) · 99.1
FY-2024 8-K (2025-02-27) · 99.1  |  8-K (2025-01-13) · 99.1
Q3-2024 8-K (2024-11-06) · 99.1 · 99.2
Q2-2024 8-K (2024-08-07) · 99.1
Q1-2024 8-K (2024-05-08) · 99.1
FY-2023 8-K (2024-03-18) · 99.1  |  8-K (2024-02-07)
Q3-2023 8-K (2023-11-08) · 99.1
Q2-2023 8-K (2023-08-07) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Cash Flows
Notes
401(k) Savings Plan
—
Collaboration Agreements
Commitments and Contingencies
Common Stock
—
Cybersecutity Risk Management, Strategy, and Governance
—
Equity Incentive Plans
—
Fair Value Measurements
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Leases
—
Marketable Securities
Nature of The Business and Basis of Presentation
Net Income (loss) Per Share
—
Net Loss Per Share
Pay Vs Performance Disclosure
Redeemable Convertible Preferred Stock
Segment Information
Stock-based Compensation
—
Stockholders' Equity
—
Subsequent Event
—
Summary of Significant Accounting Policies
Supplemental Balance Sheet Information